Intellicell Biosciences Inc Financial Statements (2025 and earlier)
Company Profile
| Business Address |
30 EAST 76TH STREET, 6TH FLOOR NEW YORK, NY 10021 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2014 Q3 | 6/30/2014 Q2 | 3/31/2014 Q1 | 12/31/2013 Q4 | 9/30/2013 Q3 | 6/30/2013 Q2 | 3/31/2013 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 336 | 0 | |||||||
| Cash and cash equivalent | 336 | 0 | |||||||
| Receivables | 57 | 67 | 192 | ||||||
| Prepaid expense | |||||||||
| Other current assets | 9 | 125 | |||||||
| Other undisclosed current assets | 321 | 664 | |||||||
| Total current assets: | 321 | 1,000 | 9 | 182 | 67 | 192 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 2,495 | 2,569 | 2,670 | 2,776 | 2,892 | 2,989 | |||
| Restricted cash and investments | 650 | ||||||||
| Other undisclosed noncurrent assets | 527 | 530 | 534 | 762 | 750 | 137 | |||
| Total noncurrent assets: | 3,021 | 3,099 | 3,205 | 3,538 | 3,642 | 3,776 | |||
| TOTAL ASSETS: | 3,343 | 4,099 | 3,214 | 3,721 | 3,709 | 3,968 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 1,005 | 1,228 | 2,609 | 3,697 | 2,719 | 2,880 | |||
| Interest and dividends payable | |||||||||
| Employee-related liabilities | 296 | 301 | 434 | 434 | 437 | 371 | |||
| Accounts payable | 646 | 599 | 2,021 | 2,053 | 1,798 | 1,998 | |||
| Accrued liabilities | 45 | ||||||||
| Other undisclosed accounts payable and accrued liabilities | 64 | 328 | 154 | 1,210 | 485 | 467 | |||
| Debt | 1,178 | 896 | 841 | 1,726 | 1,450 | 1,433 | |||
| Derivative instruments and hedges, liabilities | 9,095 | ||||||||
| Deferred revenue and credits | 374 | 373 | |||||||
| Due to related parties | 381 | 305 | 1,456 | 1,340 | 1,228 | ||||
| Other undisclosed current liabilities | 3,607 | 3,029 | 5,838 | 3,691 | 4,983 | 2,532 | |||
| Total current liabilities: | 15,641 | 5,829 | 9,288 | 10,570 | 10,493 | 8,074 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed noncurrent liabilities | 15,128 | 3,775 | 7 | 82 | 332 | ||||
| Total noncurrent liabilities: | 15,128 | 3,775 | 7 | 82 | 332 | ||||
| Total liabilities: | 15,641 | 20,957 | 13,063 | 10,576 | 10,575 | 8,406 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (12,298) | (16,858) | (9,849) | (6,856) | (6,866) | (4,438) | |||
| Preferred stock | 1 | ||||||||
| Common stock | 258 | 204 | 92 | 124 | 79 | 61 | |||
| Additional paid in capital | 48,608 | 46,808 | 38,961 | 37,573 | 35,791 | 34,322 | |||
| Accumulated deficit | (61,165) | (63,871) | (48,903) | (44,554) | (42,737) | (38,821) | |||
| Other undisclosed equity, attributable to parent | 1 | 1 | 1 | 1 | 1 | ||||
| Total equity: | (12,298) | (16,858) | (9,849) | (6,856) | (6,866) | (4,438) | |||
| TOTAL LIABILITIES AND EQUITY: | 3,343 | 4,099 | 3,214 | 3,721 | 3,709 | 3,968 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 9/30/2014 Q3 | 6/30/2014 Q2 | 3/31/2014 Q1 | 12/31/2013 Q4 | 9/30/2013 Q3 | 6/30/2013 Q2 | 3/31/2013 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 33 | 33 | ||||||
| Cost of revenue (Cost of Product and Service Sold) | (3) | (5) | ||||||
| Gross profit: | 30 | 28 | ||||||
| Operating expenses | (1,271) | (1,629) | (1,484) | (1,265) | (1,234) | (1,538) | ||
| Operating loss: | (1,241) | (1,601) | (1,484) | (1,265) | (1,234) | (1,538) | ||
| Nonoperating income (expense) | 3,947 | (8,639) | (2,866) | (552) | (2,682) | 479 | ||
| Investment income, nonoperating | (888) | 3,768 | (655) | |||||
| Interest and debt expense | (61) | (260) | 184 | 228 | (2,894) | (45) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | 2,646 | (10,500) | (4,166) | (1,589) | (6,810) | (1,103) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 61 | 260 | (184) | (228) | 2,894 | 45 | ||
| Income (loss) from continuing operations: | 2,706 | (10,240) | (4,349) | (1,817) | (3,916) | (1,058) | ||
| Income (loss) before gain (loss) on sale of properties: | 2,706 | (10,240) | (4,349) | (1,817) | (3,916) | (1,058) | ||
| Net income (loss) available to common stockholders, diluted: | 2,706 | (10,240) | (4,349) | (1,817) | (3,916) | (1,058) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2014 Q3 | 6/30/2014 Q2 | 3/31/2014 Q1 | 12/31/2013 Q4 | 9/30/2013 Q3 | 6/30/2013 Q2 | 3/31/2013 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 2,706 | (10,240) | (4,349) | (1,817) | (3,916) | (1,058) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 2,706 | (10,240) | (4,349) | (1,817) | (3,916) | (1,058) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.